[go: up one dir, main page]

PE20050445A1 - Forma de presentacion del naproxeno sodico - Google Patents

Forma de presentacion del naproxeno sodico

Info

Publication number
PE20050445A1
PE20050445A1 PE2004001035A PE2004001035A PE20050445A1 PE 20050445 A1 PE20050445 A1 PE 20050445A1 PE 2004001035 A PE2004001035 A PE 2004001035A PE 2004001035 A PE2004001035 A PE 2004001035A PE 20050445 A1 PE20050445 A1 PE 20050445A1
Authority
PE
Peru
Prior art keywords
weight
sodium
tablet
core
naproxen
Prior art date
Application number
PE2004001035A
Other languages
English (en)
Inventor
Peter Gruber
Martin Siegmund
Original Assignee
Bayer Consumer Care Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34529359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20050445(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Consumer Care Ag filed Critical Bayer Consumer Care Ag
Publication of PE20050445A1 publication Critical patent/PE20050445A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A COMPRIMIDOS NO EFERVECENTES PARA LA ADMINISTRACION ORAL DEL NAPROXENO SODICO O EL ACIDO (S)-2-(6-METOXI-2-NAFTIL)PROPIONICO QUE COMPRENDEN UN NUCLEO DE COMPRIMIDO Y SI SE DESEA UN RECUBRIMIENTO DE AZUCAR O DE UNA PELICULA SOBRE EL NUCLEO DEL COMPRIMIDO DONDE EL NUCLEO CONSTA DE 30% A 99% EN PESO DE NAPROXENO Y DE 70 HASTA 1% EN PESO DE COMPONENTES DE SUSTANCIAS AUXILIARES QUE COMPRENDEN AL MENOS UN ELEMENTO AUXILIAR BASICO RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. EL NUCLEO DEL COMPRIMIDO CONSTA DE 30% A 95% EN PESO DE NAPROXENO SODICO, ENTRE 60% A 75% EN PESO DE NAPROXENO SODICO, ENTRE OTROS. EL COMPRIMIDO PRESENTA UN CONTENIDO DE AGUA DE 0,05 A 14% EN PESO Y SUSTANCIAS AUXILIARES BASICAS EN UNA CANTIDAD TOTAL MINIMA DE UN 5% EN PESO, RESPECTO AL PESO DEL NUCLEO DEL COMPRIMIDO. LA SUSTANCIA AUXILIAR BASICA SE ELIGE DE BICARBONATO SODICO, POTASICO CARBONATO SODICO, ENTRE OTROS. LA SUSTANCIA AUXILIAR SE SELECCIONA ADEMAS DE AZUCARES, HEXOSAS, ALMIDONES, CICLODEXTRINAS, POLIVINILPIRROLIDONAS, MALTODEXTRINA, ENTRE OTROS. EL COMPRIMIDO COMPRENDE ADEMAS UN DISGREGANTE SELECCIONADO DE CROSCARMELOSA, CROSPOVIDONA, ALMIDON DE CARBOXIMETILO SODICO RETICULADO; UN TENSIOACTIVO SELECCIONADO DE LAURILSULFATO SODICO, DODECILSULFATO SODICO, POLISORBATO, ENTRE OTROS
PE2004001035A 2003-10-30 2004-10-27 Forma de presentacion del naproxeno sodico PE20050445A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH18482003 2003-10-30

Publications (1)

Publication Number Publication Date
PE20050445A1 true PE20050445A1 (es) 2005-06-18

Family

ID=34529359

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001035A PE20050445A1 (es) 2003-10-30 2004-10-27 Forma de presentacion del naproxeno sodico

Country Status (15)

Country Link
US (1) US20070134317A1 (es)
EP (1) EP1684728B1 (es)
JP (1) JP2007509862A (es)
AR (1) AR046213A1 (es)
AT (1) ATE442840T1 (es)
BR (1) BRPI0415624A (es)
CA (1) CA2543709A1 (es)
CR (1) CR8406A (es)
DE (1) DE602004023220D1 (es)
EC (1) ECSP066587A (es)
ES (1) ES2333332T3 (es)
PA (1) PA8616101A1 (es)
PE (1) PE20050445A1 (es)
UY (1) UY28583A1 (es)
WO (1) WO2005041938A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3216445A1 (en) * 2004-05-28 2017-09-13 Imaginot Pty Ltd. Oral therapeutic compound delivery system
EP1863460B1 (en) 2005-03-22 2013-01-16 Losan Pharma GmbH Solubilized ibuprofen
JP2009517346A (ja) * 2005-11-28 2009-04-30 イメイジノット ピーティーワイ エルティーディー 治療用化合物の経口送達系
GB201506755D0 (en) * 2015-04-21 2015-06-03 Reckitt Benckiser Llc Novel pharmaceutical formulation
CA3001337C (en) * 2015-10-09 2023-12-12 Reckitt Benckiser Llc Pharmaceutical formulation
JP7163015B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 経口固形組成物
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬
US11779541B2 (en) 2019-03-26 2023-10-10 Johnson & Johnson Consumer Inc. Immediate release dosage form

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US5034416A (en) * 1988-01-19 1991-07-23 Smith Walton J Carboxylic acid compositions
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
JPH10298072A (ja) * 1997-04-17 1998-11-10 Panacea Biotec Ltd 非ステロイド性抗炎症剤の遷移金属錯体
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US6383515B2 (en) * 1999-05-28 2002-05-07 Sawyer Maryjean Solvent system for enhancing solubility
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2002083110A2 (en) * 2001-04-10 2002-10-24 Zagros Pharma, Inc. Animal model for evaluating analgesics
AU2002258013A1 (en) * 2001-04-10 2002-10-28 Fakhreddin Jamali Animal model for evaluating analgesics

Also Published As

Publication number Publication date
ATE442840T1 (de) 2009-10-15
ES2333332T3 (es) 2010-02-19
EP1684728A1 (en) 2006-08-02
UY28583A1 (es) 2005-05-31
ECSP066587A (es) 2006-10-17
JP2007509862A (ja) 2007-04-19
AR046213A1 (es) 2005-11-30
US20070134317A1 (en) 2007-06-14
CA2543709A1 (en) 2005-05-12
EP1684728B1 (en) 2009-09-16
PA8616101A1 (es) 2005-08-04
DE602004023220D1 (de) 2009-10-29
WO2005041938A1 (en) 2005-05-12
BRPI0415624A (pt) 2006-12-12
CR8406A (es) 2008-04-25

Similar Documents

Publication Publication Date Title
AR110010A2 (es) Composición farmacéutica formulada en una forma de dosis única de 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo
ES2606342T3 (es) Composiciones para el cuidado bucal de sal estannosa y tripoli-fosfato de sodio y métodos
HRP20110094T8 (en) Solid preparation comprising alogliptin and pioglitazone
BRPI1007945C1 (pt) composição farmacêutica, comprimido, e, usos de nitazoxanida ou de um seu análogo
DE60313956D1 (de) Pharmazeutische iressa zusammensetzung enthaltend ein wasserlösliches cellulosederivat
PE20050445A1 (es) Forma de presentacion del naproxeno sodico
BRPI0309457A2 (pt) composições para cuidados pessoais que contém um material contendo zinco em uma composição aquosa de tensoativo.
BRPI0507342A (pt) sólidos supersaturados estabilizados de fármacos lipofìlicos
ATE493973T1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
AR067077A1 (es) Preparado solido farmaceutico y metodo de produccion del mismo
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
JP2009538268A5 (es)
NO20083027L (no) Kontrollert frigivelses-fastformpreparat
ES2113389T3 (es) Formulas orales de dosificacion mejoradas de nucleosidos de didesoxipurina.
AR066924A1 (es) Formulacion de nevirapina de liberacion prolongada
NO20072512L (no) Dispenser for halvfaste farmasoytiske eller kosmetiske preparater i posepakning
FR2912915B1 (fr) Film a desintegration rapide pour l'administration buccale de substances actives.
CL2003002588A1 (es) Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t
CO5670371A2 (es) Composiciones limpiadoras en la forma de una tableta
PE20100467A1 (es) Compuesto mono-l-malato (r)-3-((e)-2-(pirrolidin-3-il)vinil)-5-(tetrahidropiran-4-iloxi)piridina y composiciones que lo contienen
DE60335413D1 (de) Essbare, sich auflösende gelatinestreifen
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
CY1110478T1 (el) Φαρμακευτικη συνθεση που προοριζεται για χορηγηση απο το στομα ενος παραγωγου πυραζολο-3-καρβοξαμιδιου
NO20050337L (no) Oral doseringsform omfattende en flytende formulering av et aktivt middel samt en kontrollert frigivning derav ved hjelp av osmotisk ekspanderbart preparat
AR035489A1 (es) 4-fenil-1-(1-fenil-ciclohexil)-1,2,3,6,-tetrahidropiridinas sustituidas, procedimientos para su preparacion, medicamentos que contienen estos compuestos y el uso de estas sustancias para la preparacion de medicamentos

Legal Events

Date Code Title Description
FC Refusal